ITRM Key Statistics, Chart & Performance
The current stock price of ITRM is 0.3091 USD. In the past month the price decreased by -11.74%. In the past year, price decreased by -78.38%.
ITRM Technical Analysis
ITRM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ITRM. ITRM may be in some trouble as it scores bad on both profitability and health.
ITRM Financial Highlights
Over the last trailing twelve months ITRM reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 63.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ITRM Forecast & Estimates
8 analysts have analysed ITRM and the average price target is 5.61 USD. This implies a price increase of 1714.95% is expected in the next year compared to the current price of 0.3091.
ITRM Ownership
ITRM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 32.98 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.28 | 564.909B | ||
| MRK | MERCK & CO. INC. | 21.87 | 293.697B | ||
| PFE | PFIZER INC | 8.92 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.49 | 117.3B | ||
| ZTS | ZOETIS INC | 18.49 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.42 | 25.214B | ||
| VTRS | VIATRIS INC | 5.69 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.14 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.14 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ITRM
Company Profile
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Company Info
ITERUM THERAPEUTICS PLC
3 Dublin Landings, North Wall Quay
DUBLIN DUBLIN 2 IE
CEO: Corey N. Fishman
Employees: 9
Phone: 35319038354
ITERUM THERAPEUTICS PLC / ITRM FAQ
What does ITERUM THERAPEUTICS PLC do?
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
What is the current price of ITRM stock?
The current stock price of ITRM is 0.3091 USD. The price decreased by -1.56% in the last trading session.
Does ITRM stock pay dividends?
ITRM does not pay a dividend.
What is the ChartMill rating of ITERUM THERAPEUTICS PLC stock?
ITRM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for ITRM stock?
8 analysts have analysed ITRM and the average price target is 5.61 USD. This implies a price increase of 1714.95% is expected in the next year compared to the current price of 0.3091.
Can you provide the number of employees for ITERUM THERAPEUTICS PLC?
ITERUM THERAPEUTICS PLC (ITRM) currently has 9 employees.
What is the ownership structure of ITERUM THERAPEUTICS PLC (ITRM)?
You can find the ownership structure of ITERUM THERAPEUTICS PLC (ITRM) on the Ownership tab.